Active agent from the Caribbean sea cucumber could improve treatment for malignant pleural mesothelioma

October 24, 2016
Active agent from the Caribbean sea cucumber could improve treatment for malignant pleural mesothelioma. Credit: Medical University of Vienna

Researchers at the Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital have discovered a new option for treating malignant pleural mesothelioma. For the first time in the world, they were able to show in a preclinical study, both in the cell culture and in the animal model, that trabectedin, a chemotherapy drug that is already successfully used for other types of cancer, is also effective against malignant pleural mesothelioma. The active agent originally occurs in the Caribbean sea cucumber, a marine-dwelling tunicate. The study results were recently published in Molecular Cancer Therapeutics, the therapy-oriented journal of the American Association for Cancer Research (AACR). The initial interim results of a clinical study from Italy confirm these results and show that they are transferable to clinical practice.

With around 90 new cases per year in Austria, is one of the rarer forms of cancer. However, it is on the increase. Malignant pleural mesothelioma is a very aggressive form of cancer that is associated with asbestos and is routinely treated with a combination of chemotherapy, surgery and radiotherapy. Since this particular type of tumour often develops resistance to chemotherapy and radiotherapy, the prognosis is very poor.

In order to improve the treatment options for pleural mesothelioma, an interdisciplinary research cooperative was set up at the CCC in 2008 and this has been very successful in the preclinical discovery and development of therapeutics to treat malignant pleural mesothelioma. In its latest , the platform scientists investigated the action of trabectedin in malignant pleural mesothelioma. Trabectedin is an active substance that occurs in the Caribbean sea cucumber, can be synthetically manufactured for therapeutic purposes and has already been successfully used clinically for malignant soft tissue tumours and ovarian cancer.

Combination enhances effectiveness

The researchers led by Walter Berger, Deputy Head of MedUni Vienna's Institute for Cancer Research, and Alireza Hoda, Division of Thoracic Surgery at the Department of Surgery of MedUni Vienna/Vienna General Hospital, had already shown in previous works that trabectedin is very effective against cancer cells, while having minimal impact on healthy pleural cells. Furthermore, the researchers were able to demonstrate clear synergies with cisplatin, a standard therapeutic drug. In order to develop further potential combination therapies with trabectedin, the genome signatures of cells that were sensitive to the administration of trabectedin were compared with those of cell lines that were less sensitive.

Berger: "Using bioinformatics, we were able to show that the increased formation of the protein bcl-2, which prevents cell death, reduces the effectiveness of trabectedin." Consequently, the scientists treated the with a combination of trabectedin and the bcl-2 inhibitors obatoclax and venetoclax. Hoda: "When trabectedin is combined with these bcl-2 inhibitors, there is a significant improvement in destruction of malignant pleural mesothelioma cells. Trabectedin therefore seems to be a new, effective and safe treatment option for this disease." These preclinical results have just been confirmed by initial positive interim results from a clinical study conducted in Italy.

Berger: "The study has even been met with great interest from people affected. This is evidenced by the fact that the Comprehensive Cancer Centre publication has already been posted online and discussed in several international fora for asbestos and mesothelioma (e.g. asbestos.com)."

Explore further: Study of potential new treatment for mesothelioma open to patients

More information: M. A. Hoda et al. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro, Molecular Cancer Therapeutics (2016). DOI: 10.1158/1535-7163.MCT-15-0846

Related Stories

Study of potential new treatment for mesothelioma open to patients

September 15, 2016
The Baylor College of Medicine Mesothelioma Treatment Center at Baylor St. Luke's Medical Center has begun enrolling patients in a clinical research study looking at an investigational drug in patients with malignant pleural ...

Researchers find potential new target to treat malignant pleural mesothelioma

July 25, 2013
Malignant mesothelioma is a rare asbestos-associated malignancy with limited therapeutic options. Despite advances in the treatment, the median survival remains 12 months from the time of diagnosis. Increased understanding ...

Renal cancer drug temsirolimus shows promise against mesothelioma

May 1, 2011
A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology.

Mesothelioma surgery improves quality of life

June 9, 2016
Although surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients avoid the operation for fear it will degrade their quality of life.

Overlooked lymph nodes in rib cage have prognostic power for mesothelioma patients

October 28, 2013
For the first time, researchers from the Perelman School of Medicine at the University of Pennsylvania have shown the predictive power of a group of overlooked lymph nodes—known as the posterior intercostal lymph nodes—that ...

Statistical model may identify patients most likely to benefit from surgery for mesothelioma

September 8, 2015
A new statistical model may help predict which patients are most likely to receive life-extending benefits from surgical treatment for malignant pleural mesothelioma (MPM), according to an article in the September 2015 issue ...

Recommended for you

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

Researchers discover specific tumor environment that triggers cells to metastasize

November 21, 2017
A team of bioengineers and bioinformaticians at the University of California San Diego have discovered how the environment surrounding a tumor can trigger metastatic behavior in cancer cells. Specifically, when tumor cells ...

New study points the way to therapy for rare cancer that targets the young

November 21, 2017
After years of rigorous research, a team of scientists has identified the genetic engine that drives a rare form of liver cancer. The findings offer prime targets for drugs to treat the usually lethal disease, fibrolamellar ...

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.